利培酮与阿立哌唑治疗精神分裂症的效果比较

Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia

目的 评价利培酮与阿立哌唑治疗精神分裂症的临床疗效和安全性.方法 选择80例精神分裂症患者作为研究对象,随机分为利培酮组（40例）和阿立哌唑组（40例）,按照随机双盲对照的原则进行8周治疗.在治疗前后分别应用阳性和阴性症状量表（PANSS）、临床疗效总评量表（CGI）和副反应量表（TESS）及有关实验室检查进行疗效和安全性评估.结果 治疗8周后,两组患者PANSS评分较治疗前均显著降低（P〈0.05）,但是组间减分差异无统计学意义（P〉0.05）.治疗后,利培酮组有效率90%,阿立哌唑组有效率80%,两组差异无统计学意义（P〉0.05）.阿立哌唑组消化道反应发生率明显高于利培酮组（P〈0.05）.结论 利培酮治疗精神分裂症的疗效较阿立哌唑略好,安全性高.

Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group （ n = 40） and aripiprazole group（ n= 40）. According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale （ PANSS ）, clinical global impression （ CGI ）, treatment emergent symptom scale （TESS） and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline （ P 〈 0. 05 ） without statistica differences between groups （ P 〉 0. 05 ）. Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group （P 〈 0. 05）. Conclusion Both aripiprazole and risperidone could treat schizophrenia effectively,and risperidone showed better results.